Nyxoah’s DREAM Study Data Featured in Clinical Journal

Nyxoah SA, a Belgian medical technology company, has published data from its DREAM pivotal study in the Journal of Clinical Sleep Medicine. The study reports 12-month safety and efficacy results for the Genio® system, focused on the treatment of Obstructive Sleep Apnea (OSA). The findings offer a detailed assessment of the device's performance, highlighting new data on usage and patient satisfaction.

Key results show that over 70% of nights, the device was used in over 84.3% of participants. Additionally, 90% of participants expressed satisfaction, with snoring scores significantly reduced. The study had 115 participants, confirming significant improvements in apnea and oxygen levels. Safety was consistent with similar therapies, despite 11 serious adverse events.

The Genio® system's design aims to address real patient needs, with proven outcomes enhancing both patient and bedpartner sleep quality. As Nyxoah continues its path towards broader regulatory approval, these results reinforce the potential of Genio in improving OSA patient care.